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Survival benefits of revascularization in patients
with critical limb ischemia and renal insufficiency
Jana Ortmann, MD,a,b,d Brigitta Gahl, MD,b Nicolas Diehm, MD,a Florian Dick, MD,b
Tobias Traupe, MD,c and Iris Baumgartner, MD,a Bern, Switzerland
Background: Evidence for the best treatment strategy for patients with critical limb ischemia (CLI) at different stages of
renal insufficiency (RI) is rare. Therefore, we determined the benefit of revascularization vs medical therapy (MT) only in
CLI patients with different levels of RI.
Methods: This intention-to-treat cohort study with follow-up at 2, 6, and 12months was conducted in a consecutive series
of 351 patients with CLI. Revascularization by surgical (78 patients) or endovascular techniques (191 patients) was
performed in 269 patients. MT as first-line therapy was administered in 82 patients. Patients were grouped according to
glomerular filtration rate (GFR), estimated with theModification of Diet in Renal Disease equation, into absent/mild RI
(estimatedGFR [eGFR],>60mL/min/1.73m2), moderate RI (eGFR, 30-59mL/min/1.73m2), and severe RI (eGFR,
<30mL/min/1.73m2 or dialysis). Primary outcomemeasures were overall and amputation-free survival. Cox regression
models adjusted for baseline characteristics after Kaplan-Meier survival estimates were performed.
Results: The mean age differed significantly between groups (P < .001), and patients with absent/mild RI were more
often men (P < .001) or smokers (P < .001) and less often hypertensive (P < .001). Risk factor adjustment showed that
revascularized CLI patients with absent/mild RI had a longer amputation-free survival (hazard ratio [HR], 0.46; 95%
confidence interval [CI], 0.26-0.82; P .008), higher limb salvage (HR, 0.29; 95% CI, 0.17-0.91; P< .029), and better
clinical success than MT patients (HR, 0.33; 95% CI, 0.17-0.65; P  .001). The moderate RI group benefited from
revascularization in overall survival (HR, 0.51; 95% CI, 0.26-0.99; P  .049), amputation-free survival (HR, 0.51; 95%
CI, 0.29-0.90; P  .020), and clinical success (HR, 0.42; 95% CI, 0.22-0.80; P  .008). A beneficial effect on overall
survival was found even in patients with severe RI when revascularized (HR, 0.33; 95% CI, 0.12-0.91; P .032 vs MT).
Conclusions: Patients with CLI may benefit from revascularization compared with MT alone at all levels of renal
impairment. Thus, revascularization should not be withheld in CLI patients at any level of RI. (J Vasc Surg 2012;56:
737-45.)
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mCritical limb ischemia (CLI) represents the most severe
form of peripheral arterial disease, causing ischemic rest
pain and tissue loss,1 and is frequently correlated with renal
insufficiency (RI).2-4 Revascularization is the currently rec-
ommended primary treatment option for patients with CLI
because revascularized patients with CLI have a higher
survival rate and a better quality of life than patients who
receive medical treatment (MT) only.5,6 Technical success
and beneficial clinical outcomes have been shown for sur-
gical and endovascular procedures in patients with CLI.7-11
The literature is replete with studies demonstrating
poor survival and high amputation rates in the subgroup of
CLI patients with end-stage renal disease (ESRD) under-
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herefore, some authors advocate a policy of favoring MT
n patients presenting with extensive ulcerations due to CLI
s well as ESRD.13 Although studies have evaluated the
utcome of surgical revascularization according to esti-
ated glomerular filtration rate (eGFR),15,16 it is not clear
hether revascularization independent of revascularization
echnique used is beneficial or whether MT would be a
etter treatment option in patients with absent/mild, mod-
rate, or severe RI. Hence, by analyzing an all-comers
ohort of patients with CLI, we aimed to characterize the
ffect of revascularization vs MT not only in patients with
evere RI but also in those with milder levels of RI to
mprove clinical decision making in these patients.
ETHODS
Approval for this study was obtained from the Cantonal
thic Committee (Ministry of Health, Canton of Bern,
witzerland, KEK-No. 108/02). The study was conducted
ccording to the Declaration of Helsinki, and all patients
ave informed consent before inclusion into the study.
Study design. The study design of this trial has been
escribed previously.17 Briefly, 383 consecutive patients
ith chronic CLI presenting to the Swiss Cardiovascular
enter at the University Hospital, Bern, between January
999 and June 2004 were prospectively monitored for 12
onths. The definition of CLI followed current consensus
t inclusion time: (1) presence of ischemic rest pain for 2
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September 2012738 Ortmann et alweeks or ischemic tissue loss associated with (2) an absolute
ankle pressure of50 mmHg or great toe pressure of30
mm Hg, or both.18,19 Patients with acute limb ischemia
were excluded.
The analysis excluded 32 patients owing to withdrawal
of informed consent for inclusion into the study (n  1),
lack of any follow-up data owing to relocation to other
cantons or countries (n 15), and primary major amputa-
tion, which was necessary because of CLI unsuitable for
revascularization or advanced foot necrosis, with or with-
out secondary infection (n  16). Finally, 351 patients
were accepted for analysis.
For this intention-to-treat analysis, patients were in-
cluded into one of the following cohorts according to the
primary therapeutic decisions at the first time of presenta-
tion with CLI in our out-patient clinic: (1) MT; (2) revas-
cularization, including bypass grafting surgery and
endovascular revascularization, with or without stenting
(percutaneous transluminal angioplasty [PTA]). Even
when treatment options were reconsidered, patients were
kept in their initial groups and were not relocated into
another group (intention-to-treat analysis). MT was ap-
plied equally to all treatment cohorts and consisted of the
below-mentioned pharmacologic treatment.
Treatment decision. All patients were evaluated on a
case-by-case basis by a dedicated multidisciplinary vascular
board, including interventional angiologists, radiologists,
and vascular surgeons, established according to interna-
tional recommendations.18,20 The treatment decision at
baseline and during follow-up regarding the need for de-
layed or repeated revascularization and amputation was
determined by clinical presentation, urgency of therapy, the
patient’s general condition, such as presence of limiting
comorbidities, as well as the morphologic nature of the
vascular lesions, including anatomic distribution, availabil-
ity of autologous veins, and access for endovascular ther-
apy.21
Criteria for patients chosen for primary amputation
were mostly these clinical criteria, in particular, extensive
ulceration with superinfection, poor general health status,
or higher mean age (80 2.8 years). Decisions on repeated
extremity revascularizations were invariably based on vas-
cular imaging in addition to the above-mentioned clinical
findings.
MT included analgesic, antibiotic, antiplatelet, and an-
tithrombotic therapy. Prostaglandins were used infre-
quently. Risk factors were treated with lipid-lowering, an-
tihypertensive, and antidiabetic drugs.21,22
Patients who underwent primary amputation owing to
irreversible ischemic damage were registered for descriptive
analysis but were excluded from the study.
Data collection. Recorded patient details included
demographic characteristics, risk factors, clinical presenta-
tion, imaging studies, treatment modality at baseline, and
prospective follow-up data at 2, 6, and 12 months. Assess-
ment of the peripheral circulation was performed at base-
line and at each follow-up visit. A complete noninvasive
vascular workup included systolic blood pressure measure- dent of the anterior and posterior tibial arteries with cal-
ulation of ankle-brachial index (ABI) as well as oscillomet-
ic volume recordings (n  348). Transcutaneous pressure
f oxygen (TcPO2; n 188) or great toe pressure measure-
ents (n  111) were performed when both the anterior
nd posterior tibial arteries were incompressible or pres-
ures were not detectable (n  97), or when supplemental
easurements seemed necessary.23
Imaging studies were limited to patients with clinical
ymptoms suggestive of recurrent stenosis, occlusion, or de
ovo arterial obstruction, such as persistent pain and wors-
ning ulceration, together with worse parameters in the
oninvasive vascular workup. Grading of the severity of
linical disease followed the classification system proposed
y Rutherford et al.19 Ulcerations were classified according
o the Wagner classification as:
● grade 0, no open lesion with or without deformity or
cellulitis;
● grade 1, superficial ulcer, partial or full-thickness;
● grade 2, ulcer extends to ligament, tendon, joint cap-
sule or deep fascia without abscess/osteomyelitis;
● grade 3, deep ulcer with abscess, osteomyelitis, or joint
sepsis;
● grade 4, gangrene localized to forefoot or heel, and
● grade 5, extensive gangrene.24
Treatment cohorts. Patients were grouped according
o level of renal function as stated by the National Kidney
oundation–Kidney Disease Outcomes Quality Initiative
NKF-K/DOQI) guidelines.25 For comparative reasons,
e assembled stage 1 (n  46) and 2 (n  108) as well as
tage 4 (n  22) and 5 (n  21) and established three
roups: absent/mild RI (eGFR, 60 mL/min/1.73 m2),
oderate RI (eGFR, 30-59mL/min/1.73m2), and severe
I (eGFR, 30 mL/min/1.73 m2 or dialysis) as sug-
ested.2,15,26
End point analysis. Primary outcome measures were
verall and amputation-free survival and secondary out-
ome measures were limb salvage and clinical success. Clin-
cal success was defined as clinical improvement without the
eed for repeated revascularization of the target extremity
nd without major amputation. In this context, clinical
mprovement was defined according to Rutherford et al as
n upward shift of at least one clinical category for all
ategories except for baseline category 5 (upward shift of at
east two clinical categories) combined with a hemody-
amic improvement of the ABI or the toe brachial index
both of at least 0.1) or oscillometric reading. Primary
echnical success was defined as successful angioplasty with
residual diameter reduction of 30% on the procedural
ompletion angiogram. Loss of postoperative graft patency
as defined as occlusion or requirement of a subsequent
rocedure to restore or maintain functional patency as-
essed by postoperative duplex scanning.
Definitions. The following definitions were used: ar-
erial hypertension was assumed if systolic blood pressure
as140 mmHg or diastolic90 mmHg at least on two
ifferent occasions, or if the patient was taking antihyper-
s
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Volume 56, Number 3 Ortmann et al 739tensive medication. Dyslipidemia was defined by a total
serum cholesterol level of5mmol/L, serum high-density
lipoprotein cholesterol level of 1 mmol/L, or serum
triglyceride level of 2 mmol/L and was assumed if a
patient was taking lipid-lowering drugs. Diabetes mellitus
was defined by fasting blood glucose levels 120 mg/dL,
a hemoglobin A1c level 6%, or intake of antidiabetic
drugs. Current smoking habits were divided into smoking
or nonsmoking. ABI was calculated by the ratio of the
highest systolic arterial pressure reading of both tibial ar-
teries and brachial artery blood pressure. Tibial artery in-
compressibility was assumed when ABI was 1.3 because
this cutoff value has been reported to be invariably associ-
ated with heavy continuous calcification of tibial vessels.23
Amputations were considered major and thus registered if
performed above the ankle.
Statistical analysis. Kaplan-Meier estimates of cumu-
lative probabilities of overall and amputation-free survival
were calculated separately for revascularization and MT in
all patients and analyzed separately for absent/mild, mod-
erate, and severe RI. If more than one limb per patient was
recorded, one limb was randomly selected for analysis. We
used univariable and multivariable Cox proportional haz-
ard models to compare rates of all primary and secondary
end points between revascularization andMT in all patients
and stratified by absent/mild, moderate, and severe RI.
Multivariable Cox models were adjusted for risk factors
such as age, diabetes, hypertension, smoking, hyperlipid-
emia, and Rutherford class. Differences of primary and
secondary outcomes were assessed by Cox regression mod-
els, including interaction terms, among groups of RI and
treatment modality. Baseline characteristics were compared
between patients with revascularization and medical ther-
apy using 2 tests derived from univariable linear or logistic
regression models. All P values and 95% confidence inter-
vals (CI) were two-sided.
RESULTS
Cohort description. This study accepted 351 patients
for analysis; of these, 82 (23%) were treated by MT and
revascularization was performed in 269 (77%). Specifically,
191 patients were treated by endovascular means (71%,
PTA cohort) and 78 patients underwent bypass surgery
(29%; Table I). Of the patients treated by PTA, 19 (10%)
revascularized lesions were located in the iliac artery, 91
(48%) in the femoral, and 118 (62%) in the crural arteries.
Stents were used in 19 lesions (10%). In the surgery group,
five (6%) were treated by Y-prosthesis, four (5%) by com-
mon femoral endarterectomy, and five (6%) by crossover
bypass. The bypass was above the knee in 59 (76%) and
below the knee in 64 (82%). The bypass material was
autologous vein in 38 (54%), synthetic graft in 32 (41%),
and biograft in two (2%).
Baseline characteristics. Baseline characteristics of
patients with CLI across the RI groups are summarized in
Table I. The mean age differed significantly between
groups (P  .001), and a significantly larger proportion of
patients with absent/mild RI were men (P  .001) and Pmokers (P  .001), and fewer had hypertension (P 
001). No significant differences were seen with respect to
ther risk factors or clinical presentation at baseline. Base-
ine characteristics of the MT vs immediate revasculariza-
ion group showed that patients of theMT group presented
ith lower toe pressures (P  .001) and TcPO2 (P  .03),
ut were similar with respect to sex, age, other risk factors,
r clinical presentation at baseline compared with the im-
ediate revascularization group (Table II, online only).
owever, toe pressures and TcPO2 were only measured
hen ABI was not detectable or incompressible or when
urther hemodynamic evaluation seemed necessary.
nd point analysis
Amputation-free survival as a result of revascular-
zation compared withMT according to levels of RI. In
he overall cohort, amputation-free survival was signifi-
antly prolonged by immediate revascularization (hazard
atio [HR], 0.58; 95% CI, 0.41-0.82; P  .002; Fig 1, A)
nd also when Cox regression analysis was performed (HR,
.45; 95% CI, 0.31-0.64; P  .001). Amputation-free
urvival was significantly better in CLI patients with
bsent/mild RI (HR, 0.52; 95% CI, 0.30-0.89; P  .017;
igs 1, A and 2, A) and moderate RI (HR, 0.53; 95% CI,
.31-0.91; P .020; Figs 1,A and 2, C) when treated by
evascularization, whereas patients with severe RI did
ot benefit (HR, 0.58; 95% CI, 0.24-1.39; P  .224;
igs 1, A and 2, E). Multivariable adjustment showed
hese beneficial effects were still present in patients with
bsent/mild (HR, 0.46; 95% CI, 0.26-0.82; P  .008)
nd moderate RI (HR, 0.51; 95% CI, 0.27-0.90; P 
020; Fig 1, A).
Overall survival as a result of revascularization com-
ared with MT according to levels of RI. Overall sur-
ival tended to be prolonged in all CLI patients when
evascularized and not treated with MT only (HR, 0.67;
5% CI, 0.44-1.01; P  .056; Fig 1, B). A trend toward
onger overall survival was also seen when revascularization
as performed in patients with moderate (P  .078) and
evere RI (P  .069; Figs 1, B and 2, D and F). After
djustment for risk factors, overall survival was higher in the
evascularization group of the overall cohort compared
ith MT (HR, 0.46; 95% CI, 0.30-0.71; P  .001), and
his beneficial effect of revascularization was also seen in the
ubgroup of moderate (HR, 0.51; 95% CI, 0.26-0.99; P
049; Fig 1, B) and severe RI after multivariate analysis
HR, 0.33; 95% CI, 0.12-0.91; P  .032; Fig 1, B). In
ontrast, no effect of revascularization was observed in
bsent/mild RI after univariable (P  .399) or multivari-
ble analysis (P  .138; Figs 1, B and 2, B).
Clinical success as a result of revascularization com-
ared withMT according to levels of RI. Clinical success
as significantly higher in the overall cohort (HR, 0.45; 95%
I, 0.30-0.66; P .001) and also after Cox regression anal-
sis (HR, 0.34; 95% CI, 0.23-0.52; P  .001; Fig 3, A).
oreover, clinical success was significantly improved in CLI
atients with absent/mild RI (HR, 0.37; 95% CI, 0.20-0.70;
 .002) andmoderateRI (HR, 0.47; 95%CI, 0.26-0.88;P
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September 2012740 Ortmann et al.017; Fig 3,A) when treated by revascularization. Multivariable
adjustment showed these beneficial effects were still present for
absent/mild IR (HR, 0.33; 95% CI, 0.17-0.65; P .001) and
moderate IR(HR,0.42;95%CI,0.22-0.80;P .008;Fig3,A).
Limb salvage as a result of revascularization com-
pared with MT according to levels of RI. Limb salvage
was more likely in patients with absent/mild RI when
revascularized compared with MT alone (HR, 0.40; 95%
CI, 0.18-0.90; P .027). This beneficial effect of revascu-
larization was still significant when adjusted for confound-
Table I. Risk factors, treatment modality, clinical presenta
baseline presented by different stages of renal insufficiencya
Characteristic
Absent/mild RI
GFR 60 mL/
min/1.73 m2
Patients, % (n) 44 (154)
Risk factors
Age, mean (SD) years 72 (11)
Males 71 (110)
Hypertension, % (n) 66 (103)
Hyperlipidemia, % (n) 45 (69)
Smoking, % (n) 66 (102)
Diabetes, % (n) 41 (63)
Platelet inhibitor, % (n) 46 (72)
Anticoagulation, % (n) 33 (51)
Treatment modality
Medical treatment, % (n) 27 (42)
Immediate revascularization, % (n) 73 (112)
Surgery, % (n) 36 (40)
PTA, % (n) 64 (72)
Clinical presentation, % (n)
Rutherford 4 17 (26)
Rutherford 5 82 (127)
Rutherford 6 1 (1)
Hemodynamic presentation
Ankle-brachial index
Median (IQR) 0.36 (0.24-0.46)
Not measurable, % (n)b 24 (37)
TcPO2
Median (IQR) mm Hg 11 (1-19)
Not measured, % (n)b 45 (70)
Toe pressure
Median (IQR) mm Hg 24 (3-30)
Not measured, % (n)b 68 (105)
Oscillography, % (n)
Nonpulsatile reading 47 (72)
Not performed 1 (2)
Revascularized lesions, % (n)
Above knee 49 (76)
Below knee 51 (78)
Ulcus severity (Wagner score), % (n)
Stadium 0 20 (31)
Stadium 1II 67 (102)
Stadium 3, 4 (6)
Stadium 4V 9 (13)
GFR,Glomerular filtration rate; IQR, interquartile range; PTA, percutaneou
transcutaneous pressure of oxygen.
aBaseline characteristics were compared between absent/mild, moderate, and
variables are reported as mean (standard deviation), asymmetrically distribu
All P values are two-sided.
bTcPO2 (n 188) and/or great toe pressure measurements (n 111) were p
or pressures were not detectable (n  97) or when supplemental measuremers (HR, 0.29; 95% CI, 0.17-0.91; P  .029; Fig 3, B). rowever, patients with moderate or severe RI did not
enefit from revascularization, also when adjusted for risk
actors. In the severe RI group, coefficients did not con-
erge because of complete separation and low patient num-
ers. The bivariable analysis yielded a P  .309 (Fisher
xact test), with six amputations, all in the immediate
evascularization group.
Numbers and time to repeated revascularization
nalyzed by levels of RI. Time to repeated revasculariza-
ion of the target extremity was 221 days (interquartile
and hemodynamic measurements of 351 patients at
Moderate RI Severe RI
P
GFR  30-59
mL/min/1.73 m2
GFR 30 mL/
min/1.73 m2
44 (154) 12 (43)
78 (8) 74 (11) .001
44 (69) 49 (20) .001
84 (131) 88 (36) .001
56 (87) 44 (18) .225
42 (65) 44 (18) .001
49 (76) 59 (24) .140
53 (86) 63 (28) .066
29 (46) 20 (8) .185
.243
19 (30) 23 (10)
81 (124) 77 (33)
23 (28) 30 (10)
77 (96) 70 (23)
.538
21 (33) 17 (7)
76 (118) 88 (36)
2 (3) 0 (0)
0.36 (0.21-0.50) 0.39 (0.05-0.59) .601
31 (47) 26 (11) .428
14 (2-20) 12 (3-15) .426
48 (74) 44 (19) .857
19 (0-27) 23 (15-33) .147
70 (108) 63 (27) .656
43 (67) 51 (21) .612
2 (3) 0 (0) .625
.897
47 (72) 49 (21)
53 (82) 52 (22)
.518
23 (35) 17 (7)
59 (90) 59 (25)
4 (6) 4 (2)
14 (21) 19 (8)
sluminal angioplasty;RI, renal insufficiency; SD, standard deviation; TcPO2,
e renal insufficiency using 2 test. Continuous data and normally distributed
riables as median (IQR), and categoric variables as percentages (numbers).
ed when the anterior and posterior tibial arteries were both incompressible
eemed necessary.tion,
s tran
sever
ted vaange [IQR], 56-351 days) and tended to decrease along
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was not significant (P  .752), and although lower in the
severe group, the number of patients who had to undergo
a repeated revascularization was not significantly different
between groups (P  .202; Table III).
Mortality rates and causes of death analyzed by
levels of RI. In the overall CLI cohort, 1-year mortality
was 30% and the rate of 1-year mortality or amputation was
43% (Table III). The 1-year mortality (P  .007) and
1-year mortality or amputation rate (P .013) significantly
increased along with deterioration of renal function. Of
107 deaths, 25 (23%) were cardiac deaths, including heart
failure or myocardial infarction, whereas eight patients (7%)
died of renal failure. Further causes of death were sepsis and
multiorgan failure in five patients (5%) each, carcinoma in
four (4%), stroke in three (3%), and respiratory failure,
including pneumonia in two (2%) or pulmonary embolism
in one (1%). The specific cause of death was unknown in 54
patients (50%).
Early causes of death after bypass surgery were cardiac
failure in two (postinterventional days [PIDs] 1 and 9),
multiorgan failure in two (on PIDs 3 and 8), and sepsis in
one (PID 8). Early death in patients treated by endovascu-
lar means was caused, in one patient each, by renal failure
(PID 10), stroke (PID 2), multiorgan failure (PID 4),
worsening of general health status in a patient with breast
cancer (PID 11), and one death of unknown reason (PID
9). Two patients receiving MT died of renal failure only 4
days after treatment decision at our center.
DISCUSSION
The key finding of this prospective cohort study in a
Fig 1. Hazard ratios from univariable (left) and hazard
proportional hazard models compare the effects of revascu
and (B) overall survival separately for all critical limb isch
renal insufficiency (RI), moderate RI, and severe RI, resp
diabetes, hypertension, and smoking. P values were ca
proportional hazard models. GFR, Glomerular filtrationconsecutive series of an all-comers cohort of patients with dLI is that all patients with RI may benefit from revascu-
arization. Our study shows that after adjustment for risk
actors, immediate revascularization had a beneficial effect
n overall and amputation-free survival in the overall co-
ort, a finding that reflects current recommendations for
LI.1,27 This beneficial effect might be due to longer
linical success in the overall cohort when revascularized.
An important finding was that revascularized patients
ith absent/mild and moderate RI had a prolonged
mputation-free survival, which might be due to improved
linical success in these groups, even after adjustment for
isk factors. Although patients with absent/mild RI did not
ignificantly benefit from revascularization regarding over-
ll survival, we observed beneficial effects on limb salvage,
ossibly accounting for the improved amputation-free sur-
ival, which was a composite end point. In contrast, the
rolonged amputation-free survival in revascularized pa-
ients with moderate RI was possibly due to improved
verall survival because limb salvage was obviously not
ffected by revascularization. More important, even CLI
atients with severe RI had a benefit from revascularization
n overall survival, despite the lack of effect on amputation-
ree survival or limb salvage.
In detail, our analysis reveals that overall and amputation-
ree survival of revascularized patients with CLI depend on
graded classification of kidney function. For stratification,
e used groups according to eGFR as proposed earlier,
ecause ESRD and moderate RI are both correlated with
imb loss and death after surgery in CLI.15 There are studies
valuating the outcome of endovascular or surgical revas-
ularization in patients with ESRD,4,12-14 which, however,
and forest plots frommultivariable analysis (right). Cox
ation vs medical therapy on (A) amputation-free survival
(CLI) patients, and for CLI patients with absent/mild
ly. Multivariable Cox models were adjusted for age, sex,
ed using the two-sided Wald test derived from Cox-ratios
lariz
emia
ective
lculato not consider milder degrees of impaired renal function.
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tion-free survival is markedly prolonged in patients with
absent/mild as well as with moderate RI who receive
revascularization compared with patients treated by MT.
Moreover, in moderate as well as severe RI, there was a
Fig 2. Kaplan-Meier survival curves for cumulative outc
and E) amputation-free survival and (B, D, and F) ov
medical therapy (MT) for critical limb ischemia (CLI) pat
andD)moderate RI, and (E and F) severe renal insufficie
from Cox proportional hazard models. Numbers at riskbenefit from revascularization regarding overall survival when adjusted for risk factors. In recent years, few authors
ave investigated the association between eGFR and sur-
ival, and if however, after surgical revascularization
nly.2,28 O’Hare et al28 studied 9932 veterans who under-
ent surgical revascularization and corroborated that RI
estimates of primary efficacy study end points for (A, C,
survival calculated separately for revascularization and
with (A and B) absent/mild renal insufficiency (RI), (C
espectively. P values were calculated using 2 test derived
ven for patients. GFR, Glomerular filtration rate.ome
erall
ients
ncy, ras strongly correlated with death in CLI and that mortal-
w
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Volume 56, Number 3 Ortmann et al 743ity was highest in patients with severe RI (eGFR 30
mL/min/1.73 m2). In a different study, reduced eGFR
was positively associated with higher mortality rates up to 3
years after surgery.28 However, these studies investigated
surgical revascularization only and did not compare these
outcomes with those in patients treated with MT only, as
we did in the present study.
Our series not only documents an improved 1-year
survival for patients with moderate but also better survival
in severe RI when patients were treated by revasculariza-
tion, suggesting that this treatment option is worthwhile
even in advanced kidney disease. Every second patient with
Fig. 3. Hazard ratios from univariable (left) and hazard
proportional hazard models to compare the effects of rev
and (B) limb salvage separately for all critical limb ischem
insufficiency (RI), moderate RI, and severe RI, respect
diabetes, hypertension, and smoking. P values were
proportional hazard models. *In the severe RI group, coe
low patient numbers. The bivariable analysis yielded P
immediate revascularization group. GFR, Glomerular fil
Table III. Time to repeated revascularization procedures
insufficiencya
Characteristic All patients
Absent/mild
GFR 60 mL
1.73 m2
Patients, % (n) 100 (351) 44 (154)
Days to repeat
revascularization,
median (IQR) 211 (56-351) 228 (59-35
1-year rate, % (n)
Repeat revascularization of
target extremity 29 (101) 29 (45)
Mortality 30 (107) 24 (37)
Mortality or amputation 43 (153) 36 (56)
GFR, Glomerular filtration rate; IQR, interquartile range; RI, renal insuffic
aOne-year rates and time to repeated revascularization procedures, 1-year mo
insufficiency of 351 patients using 2 test. Asymmetrically distributed variable
P values are two-sided.severe RI has died after 1 year of follow-up. This is in line dith prior observations showing a cumulative survival of
6% in patients with eGFR 30 mL/min/1.73 m2.15
oreover, in the same study with 603 CLI patients under-
oing bypass surgery, 1-year survival and amputation-free
urvival rates for eGFR60, 30 to 60, and30 mL/min/
.73 m2 were almost identical to our study, underlining
gain the robustness of our patient selection.15
Contrary to the beneficial effect on overall survival, the
ffect on amputation-free survival was not significant be-
ween MT and revascularization in our patients with severe
I. When performing immediate revascularization in CLI
atients with severe RI, complications likely lead to re-
and forest plots frommultivariable analysis (right). Cox
rization vs medical therapy (MT) on (A) clinical success
I) patients, and for CLI patients with absent/mild renal
Multivariable Cox models were adjusted for age, sex,
lated using two-sided Wald test derived from Cox-
nts did not converge because of complete separation and
09 (Fisher exact test) with six amputations, all in the
n rate.
ortality rates of 351 patients analyzed by stages of renal
Moderate RI Severe RI
P
/ GFR  30-59 mL/min/
1.73 m2
GFR 30 mL/min/
1.73 m2
44 (15 4) 12 (43)
215 (62-353) 144 (33-267) .752
31 (48) 19 (8) .270
32 (49) 49 (21) .007
46 (71) 60 (26) .013
rates, and 1-year rates of mortality or amputation analyzed by stages of renal
eported as median (IQR), and categoric variables as percentages (numbers).ratios
ascula
ia (CL
ively.
calcu
fficie
 .3and m
RI
/min
7)
iency.
rtalityuced clinical success and consequently limb loss compared
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September 2012744 Ortmann et alwith patients with milder degrees of RI, although clinical
assessment at baseline using ABI, TcPO2, oscillography,
and the ulceration score was not different among groups.
Interestingly, endovascular12 as well as surgical revascular-
ization therapy4,13 of infrapopliteal arteries have been
shown to have limited efficiency in ESDR patients because
of high amputation rates. However and importantly, sur-
vival rates were improved in patients with severe RI when
revascularization therapy was performed (131 62 [SD] vs
211  26 days vs MT; P  .035). Therefore, these results
suggest that especially in these patients, MT only is not
sufficient and that they should be revascularized because
although they have a higher risk for amputation, their lives
may be saved.
Although our data show beneficial effects of revascular-
ization on overall survival in patients with severe and mod-
erate RI, this effect was not significant in the absent/mild
RI group. However, these patients did benefit from the
combined end point of amputation-free survival. On that
account, we believe that this result might be due to our
rather short follow-up time, which may reflect the short-
term benefit on limb loss but not on overall mortality.
Moreover, the lowermortality rates of our patients with less
severe forms of RI might be too low to observe significant
effects. Thus, it may be the CLI patients with advanced
disease in which an overall survival benefit of revasculariza-
tion can be demonstrated. In fact, a study by Owens et al,16
including 456 patients with bypass surgery, showed a linear
relationship between reduced eGFR and mortality rates.
Similarly, Hemmelgarn et al29 demonstrated a decrease in
survival corresponding to a decline in eGFR in a series of
8521 patients undergoing cardiac catheterization and
noted an increased mortality risk when the eGFR was 79
mL/min/1.73 m2).
Some limitations to this study merit consideration.
First, the included number of individuals with severe RI was
limited, which weakens the power of our statistical analysis
and the strength of our conclusion for this subgroup. We
therefore assembled stage 4 (n 22) and 5 (n 21) of the
classification system established by NKF-K/DOQI guide-
lines25 for statistical reasons as well as for comparability
with other studies.2,15,26 More importantly, the low case-
load of patients with RI stage 4 and 5 was also shown in the
study of Arvela et al23 who used the same classification,
which underlines the robustness of our cohort.
For practical reasons as well as for comparability, we
used the eGFR, which is an validated method,30,31 also
reported in studies correlating outcome of revasculariza-
tion in peripheral artery disease to eGFR.2,15 Further, we
used the Modified Diet in Renal Disease (MDRD) equa-
tion because it is more precise than the Cockroft-Gault
equation, especially in severe kidney disease.30,31 However,
the MDRD equation may loose accuracy in populations
without kidney disease.32 Regardless of its limitations, the
eGFR is a more accurate predictor of survival and limb
salvage after surgery in CLI patients than serum creatinine
levels alone.15 OBecause of ethical concerns, we did not randomize
atients to treatment options because immediate revascu-
arization is currently considered as the treatment of
hoice.5,6 To ensure consistency of treatment groups, each
atient was assessed by our multidisciplinary vascular
oard, in which consultants did not change during the
tudy period. Moreover, 25% of our patients received MT
s the primary treatment, which is very well in accordance
ith the TransAtlantic InterSociety Consensus (TASC II)
ocument on the management of peripheral artery dis-
ase.33
There are likely unaccounted for confounders in our
atients such as rate of RI progression, proteinuria, quality
f vein material, and level of activity (American Society of
nesthesiologists score). Therefore, bias in patient selec-
ion for treatment groups might be an issue. However,
here were equal numbers in the MT and revascularization
roups in all RI groups. Moreover, we showed that except
or toe pressure and TcPO2, patient characteristics, such as
isk factors or disease severity, were similar in the immediate
evascularization and MT groups. Therefore, we can as-
ume comparability of the MT and revascularization
roups.
The follow-up time of 1 year might be too short to
bserve significant effects on overall survival in groups with
ower mortality rates such as our moderate and absent/
ild RI group. However, our aged patients often have
imited mobility, and arranging follow-up visits to our
ertiary referral center is very difficult. Therefore, most of
he patients would not have agreed to participate in this
tudy if they would have had to present to our clinic for
ore than 1 year.
ONCLUSIONS
This study demonstrates that differences exist regard-
ng baseline characteristics between different groups of RI.
he hypothesis that higher procedural complications, co-
orbidities, and more severe disease at presentation may
avor MT in patients with severe RI is not supported by our
ata. In fact, the findings of this prospective trial reveal that
LI patients with absent/mild, moderate, and severe RI do
enefit from revascularization. Thus, an aggressive treat-
ent strategy for CLI should not be restrained from pa-
ients with any degree of renal impairment.
We thank Jolanda Vögele, RN, and Ackaterini Galima-
is, RN, for assistance in data preparation.
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erformedwhen both, the anterior and posterior tibial arteries were incompressible
ents seemed necessary.
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September 2012745.e1 Ortmann et alTable II (online only). Baseline characteristics of 351 cri
treatment modalitya
Variable
Medical treatm
(n  82)
Risk factors
Females, % (n) 46 (38)
Age, mean (SD) years 75 (10.7)
Hypertension, % (n) 77 (63)
Hyperlipidemia, % (n) 44 (36)
Smoking, % (n) 51 (42)
Diabetes, % (n) 33 (27)
Stages of RI, % (n)
Absent/mild 51 (42)
Moderate 37 (30)
Severe 12 (10)
Platelet inhibitor, % (n) 54 (44)
Clinical presentation, % (n)
Rutherford 4 26 (21)
Rutherford 5 74 (61)
Rutherford 6 0 (0)
Hemodynamic presentation
Ankle-brachial index
Median (IQR) 0.4 (0.3-0.4
Not measurable % (n)b 20 (16)
TcPO2
Median (IQR) mm Hg 14 (10-18)
Not measured, % (n)b 38 (31)
Toe pressure
Median (IQR) mm Hg 4 (1-8)
Not measured, % (n)b 71 (58)
Oscillometry, % (n)
Nonpulsatile reading 12 (10)
Not performedb 1 (1)
Revascularized lesions, % (n)
Above knee 49 (40)
Below knee 51 (42)
Ulcus severity (Wagner score), % (n)
Stage 0 26 (21)
Stages 12 59 (47)
Stage 3 4 (3)
Stages 45 11 (9)
IQR, Interquartile range; RI, renal insufficiency; SD, standard deviation; Tc
aBaseline characteristics were compared between immediate revascularizatio
variables are reported as mean (standard deviation), asymmetrically distribut
All P values are two-sided.
bTcPO2 (n 188) and/or great toe pressuremeasurements (n 111) were p
or pressures were not detectable (n  97) or when supplemental measuremtical ischemic limbs at first presentation with stratification for
ent Immediate revascularization
P(n  269)
42 (114) .532
75 (10.2) .572
77 (207) .979
51 (138) .766
50 (143) .731
51 (136) .142
.261
42 (112)
46 (124)
12 (33)
53 (142) .897
.121
16 (45)
81 (220)
1 (4)
) 0.4 (0.3-0.4) .721
27 (72) .185
11 (9-14) .032
49 (132) .073
26 (20-24) .001
68 (182) .600
19 (52) .151
1 (1) .372
.896
48 (129)
52 (140)
.637
20 (52)
64 (171)
4 (11)
12 (33)
PO2, transcutaneous oxygen pressure.
n and medical therapy using 2 test. Continuous data and normally distributed
ed variables as median (IQR), and categorical variables as percentages (numbers).
